case_images: PMC8570848_01
case_images: Graphical representation of case 1's INR and corresponding weekly warfarin dose during clinical visits.
case_images: CRIID2021-9384663.001.jpg
case_images: PMC8570848_01_CRIID2021-9384663.001.jpg
case_images: fig1
case_images: His INR remained therapeutic at 2.2 two weeks later, and his weekly dose of 42 mg was maintained.  Figure 1 shows the changes in INR and warfarin dose that have been described above.
case_images: PMC8570848_02
case_images: Graphical representation of case 2's INR and corresponding weekly warfarin dose during clinical visits.
case_images: CRIID2021-9384663.002.jpg
case_images: PMC8570848_02_CRIID2021-9384663.002.jpg
case_images: fig2
case_images: There have not been any report of bleeding or thrombosis since switching to rivaroxaban.  Figure 2 shows the changes in INR.